Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC
Status:
Recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
At present, the treatment of advanced gastric/gastroesophageal junction cancer is a research
hotspot in the academic community. In Asia, Siewert type II and type III are the main types
of advanced gastric/gastroesophageal junction cancer. The current consensus in the academic
community for the treatment of this part of the tumor is based on the principles of diagnosis
and treatment of gastric cancer, of which the value of neoadjuvant therapy in this part of
the tumor has been paid more and more attention by scholars. However, there is no highly
recognized neoadjuvant therapy. The current situation will promote the development of
advanced gastric/gastroesophageal junction cancer to accurate preoperative staging, more
accurate population screening, more accurate targets and molecular markers. Immunotherapy is
a promising application in oncology. Several PD1/PD-L1 monoclonal antibodies are approved by
FDA for the clinical treatment of melanoma and other tumors. Previous clinical studies have
shown that PD1/PD-L1 has limited efficacy in digestive tract tumors. However, on ASCO in
2020, Asian analysis of KEYNOTE-062 study showed that in HER-2 negative advanced gastric
cancer with PD-1 combined positive score (CPS) ≥ 1 and CPS ≥ 10, the OS of PD-1 inhibitor
treatment was superior to that of chemotherapy group, with 24-month OS rate (CPS ≥ 1, 45% VS
23%, CPS ≥ 10, 54% VS 27%). Meanwhile, the results of PACIFIC study phase III clinical trial
showed that the 3-year OS of PD-L1 monoclonal antibody combined with radiotherapy in advanced
unresectable lung cancer was as high as 57%, which is expected to completely rewrite its
clinical practice. Immunotherapy is promising in cancer therapy. This study intends to use
immunotherapy combined with SOX (S-1 + Oxaliplatin) as a neoadjuvant therapy for advanced
gastric/gastroesophageal junction cancer.